Symptomatic CMV disease has been the standard endpoint for clinical trials in organ transplant recipients. Viral load may be a more relevant endpoint due to low frequency of disease. We performed a meta-analysis and systematic review of the literature. We found several lines of evidence to support the validity of viral load as an appropriate surrogate end-point including 1)viral loads in CMV disease are significantly greater than in asymptomatic viremia (OR 9.3, 95%CI 4.6 to 19.3); 2)kinetics of viral replication are strongly associated with progression to disease; 3)pooled incidence of CMV viremia and disease is significantly lower during prophylaxis compared with the full patient followup period (viremia incidence: 3.2%vs.34.3%, p<0.001) (disease incidence: 1.1%vs.13.0%, p<0.001); 4)treatment of viremia prevented disease; and 5)viral load decline correlated with symptom resolution. Based on the analysis, we conclude that CMV viral load is an appropriate surrogate end-point for CMV trials in organ transplant recipients.
Pharmacology, Toxicology and Pharmaceutical Science
5
6%
Agricultural and Biological Sciences
5
6%
Biochemistry, Genetics and Molecular Biology
4
5%
Other
6
8%
Unknown
23
30%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 November 2022.
All research outputs
#4,576,513
of 27,431,437 outputs
Outputs from Clinical Infectious Diseases
#7,352
of 18,469 outputs
Outputs of similar age
#68,150
of 329,496 outputs
Outputs of similar age from Clinical Infectious Diseases
#104
of 209 outputs
Altmetric has tracked 27,431,437 research outputs across all sources so far. Compared to these this one has done well and is in the 83rd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 18,469 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 31.0. This one has gotten more attention than average, scoring higher than 60% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 329,496 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 79% of its contemporaries.
We're also able to compare this research output to 209 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 50% of its contemporaries.
